GlobeNewswire

DNAtix, the Genetics Blockchain Company, Introduces Complete Genome Sequencing Pilot and Announces Token Sale

Dela

Anonymous DNA Testing, Transfer, Storage with Total Control of Personal Data

 

AMSTERDAM, Netherlands, June 27, 2018 (GLOBE NEWSWIRE) -- Digital DNAtix Ltd., the genetics blockchain company, today announced the pilot of a breakthrough blockchain-based infrastructure and ecosystem for anonymous genetic testing, services and research. DNAtix is the first company to successfully transfer a genetic sequence over the Ethereum Blockchain. The DNAtix genetics ecosystem links individual users in the search of health solutions, or answers to ancestral questions, with products and services that fit their needs. DNAtix is also developing a dedicated Token - the DNATIX token - that will be integrated into the use of its DNAtix genetic platform.

"DNAtix is solving the privacy issue once and for all for testing highly sensitive DNA data with the first infrastructure blockchain ecosystem solution for anonymous genetic services," said Ofer A. Lidsky the CEO & CTO of the DNAtix. "Consumers, healthcare institutions, research centers, clinics, genetic counselors and others interested in using, testing, or gathering DNA data can now connect, work together for better health solutions and feel confident in sharing their genetic information."

Anyone can anonymously upload partial and/or full genome sequences onto the DNAtix platform; contributors own their genomic data and use it to make informed decisions.

Technology Breakthrough: An entire genetics ecosystem on the blockchain
Opening the door for advancements in research, new treatments, and cutting-edge personalized and preventive medicine, DNAtix's D2C platform provides full genome testing and access to services and solutions on the Blockchain and allows researchers to use anonymous DNA, stored on the DNAtix infrastructure, to create tests, do research and design new treatments.

In order to better leverage the emerging infrastructure and potential of blockchain genetic storage, DNAtix has developed and freely releases its compression algorithm for the mutual betterment of the field; Thus far, DNA storage efficiency has been increased by 300%.
GitHub repository: https://github.com/DNAtix/DNAtix-DNA-Compression-Tool

The DNATIX Token
DNAtix is in the private sale stage of its token to fund the delivery of anonymous genetic services at an affordable price point. The DNAtix token has smart contracts built into it enabling -for the first time- the anonymous and secure analysis, transfer, and storage of DNA sequences. The DNAtix wallet will facilitate anonymous payment for a wide range of genetic services. For more information and purchase instructions about DNAtix token sale, email:  info@dnatix.com.

SPEAKING: DNAtix AT BLOCKCHAIN EXPO EUROPE  
Ofer A. Lidsky will be presenting twice at Blockchain Expo Europe:

· Track:  Developing Blockchain Applications
· Day/Time:  Day 1 (27 June) 14:40 - 14:50
· Title: Introducing new developments 2 (When Blockchain Meets Genetics)
   
· Track: Blockchain Technologies
· Day/Time: Day 2 (28 June) 09:40 - 10:20
· Keynote Panel: What does the future hold for Blockchain technology - where do we think we will be in 2030?

More information: https://blockchain-expo.com/europe/speaker/senior-representative-dnatix/

ABOUT DNAtix
DNAtix, a cutting-edge genetics and blockchain company, is building the infrastructure for the world's genetic blockchain ecosystem where researchers, hospitals, developers, clinicians and others will develop next generation, decentralized genetics applications and health management solutions. DNAtix is also delivering a direct-to-consumer platform that offers anonymous and encrypted genome sequencing and genetic services, including digitized DNA analysis, storage and transfer.  The DNAtix genetics ecosystem is a place where consumers and the industry can meet to share genetic data in a more transparent, accessible, applicable and secured manner. DNAtix is developing the future ecosystem for Genetics which is Blockchain based and includes cutting edge new innovative ideas and technologies. With a first successful proof of concept already completed for transferring a DNA sequence over the Ethereum blockchain DNAtix is leading the world of Genetic blockchain.  www.dnatix.com 

Media Contact: 
Heidi Groshelle 
Groshelle Communications 
heidi@groshelle.com 
415.307.1380

A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9f9e2aca-e48d-4d99-a20f-860e3995878b 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DNAtix via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum